The clinical effect of concurrent oncogenic gene mutations in BRAF p.(V600E)-mutated NSCLC treated with dabrafenib and trametinib

P. Meng; B. Koopman; K. Kok; A. ter Elst; E. Schuuring; L. C. van Kempen; W. Timens; T. J. N. Hiltermann; H. J. M. Groen; A. van den Berg; A. J. van der Wekken

doi:10.1016/j.annonc.2020.08.1360

The clinical effect of concurrent oncogenic gene mutations in BRAF p.(V600E)-mutated NSCLC treated with dabrafenib and trametinib

P. Meng, B. Koopman, K. Kok, A. ter Elst, E. Schuuring, L. C. van Kempen, W. Timens, T. J. N. Hiltermann, H. J. M. Groen, A. van den Berg, A. J. van der Wekken

Research output: Contribution to journal › Meeting Abstract › Academic

Original language	English
Pages (from-to)	S1106-S1106
Number of pages	1
Journal	Annals of Oncology
Volume	31
DOIs	https://doi.org/10.1016/j.annonc.2020.08.1360
Publication status	Published - Sep-2020
Event	ESMO Virtual Congress - Duration: 19-Sep-2020 → 18-Oct-2020

Access to Document

10.1016/j.annonc.2020.08.1360

Cite this

Meng, P., Koopman, B., Kok, K., ter Elst, A., Schuuring, E., van Kempen, L. C., Timens, W., Hiltermann, T. J. N., Groen, H. J. M., van den Berg, A., & van der Wekken, A. J. (2020). The clinical effect of concurrent oncogenic gene mutations in BRAF p.(V600E)-mutated NSCLC treated with dabrafenib and trametinib. Annals of Oncology, 31, S1106-S1106. https://doi.org/10.1016/j.annonc.2020.08.1360

Meng, P. ; Koopman, B. ; Kok, K. ; ter Elst, A. ; Schuuring, E. ; van Kempen, L. C. ; Timens, W. ; Hiltermann, T. J. N. ; Groen, H. J. M. ; van den Berg, A. ; van der Wekken, A. J. / The clinical effect of concurrent oncogenic gene mutations in BRAF p.(V600E)-mutated NSCLC treated with dabrafenib and trametinib. In: Annals of Oncology. 2020 ; Vol. 31. pp. S1106-S1106.

@article{ed2188e7dd584407b3fa8da42c8cfc9f,

title = "The clinical effect of concurrent oncogenic gene mutations in BRAF p.(V600E)-mutated NSCLC treated with dabrafenib and trametinib",

author = "P. Meng and B. Koopman and K. Kok and {ter Elst}, A. and E. Schuuring and {van Kempen}, {L. C.} and W. Timens and Hiltermann, {T. J. N.} and Groen, {H. J. M.} and {van den Berg}, A. and {van der Wekken}, {A. J.}",

year = "2020",

month = sep,

doi = "10.1016/j.annonc.2020.08.1360",

language = "English",

volume = "31",

pages = "S1106--S1106",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

note = "ESMO Virtual Congress ; Conference date: 19-09-2020 Through 18-10-2020",

}

Meng, P , Koopman, B , Kok, K , ter Elst, A , Schuuring, E , van Kempen, LC , Timens, W , Hiltermann, TJN , Groen, HJM , van den Berg, A & van der Wekken, AJ 2020, 'The clinical effect of concurrent oncogenic gene mutations in BRAF p.(V600E)-mutated NSCLC treated with dabrafenib and trametinib', Annals of Oncology, vol. 31, pp. S1106-S1106. https://doi.org/10.1016/j.annonc.2020.08.1360

The clinical effect of concurrent oncogenic gene mutations in BRAF p.(V600E)-mutated NSCLC treated with dabrafenib and trametinib. / Meng, P.; Koopman, B.; Kok, K.; ter Elst, A.; Schuuring, E.; van Kempen, L. C.; Timens, W.; Hiltermann, T. J. N.; Groen, H. J. M.; van den Berg, A.; van der Wekken, A. J.

In: Annals of Oncology, Vol. 31, 09.2020, p. S1106-S1106.

Research output: Contribution to journal › Meeting Abstract › Academic

TY - JOUR

T1 - The clinical effect of concurrent oncogenic gene mutations in BRAF p.(V600E)-mutated NSCLC treated with dabrafenib and trametinib

AU - Meng, P.

AU - Koopman, B.

AU - Kok, K.

AU - ter Elst, A.

AU - Schuuring, E.

AU - van Kempen, L. C.

AU - Timens, W.

AU - Hiltermann, T. J. N.

AU - Groen, H. J. M.

AU - van den Berg, A.

AU - van der Wekken, A. J.

PY - 2020/9

Y1 - 2020/9

U2 - 10.1016/j.annonc.2020.08.1360

DO - 10.1016/j.annonc.2020.08.1360

M3 - Meeting Abstract

VL - 31

SP - S1106-S1106

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

T2 - ESMO Virtual Congress

Y2 - 19 September 2020 through 18 October 2020

ER -